
The Sad And Scary Truth About Reproductive Oppression And Black Women
getty
Earlier this month, an old clip of Rashida Jones' character on Netflix's #blackAF circulated social media of her referencing Black women being brought to the U.S. to breed babies. The now-viral clip has sparked debate about the accuracy of Jones's claim during the almost 20-second-long monologue. Despite arguments from critics and skeptics who question her comments, it is well documented that Black women were initially brought to the U.S. to perform various physically laborious tasks among those breeding babies -- an act that has since been referred to as reproductive oppression.
During the clip, Jones says that while some may wonder what would happen if shows like The Handmaid's Tale were true, they need not look far. The storyline of women being used and valued only as vessels to carry and deliver babies was a bitter reality for Black women in America at one time. During slavery, enslaved Black women in the United States were forcibly impregnated and exploited for their reproductive labor. This was a critical component of the slave breeding industry, which was driven by the economic need for labor and the dehumanization of enslaved people and is now referred to as reproductive oppression, which social scientists and historians refer to as the regulation, exploitation – and even in some cases, the monetization -- of individual's sexuality, labor, bodies, and procreative abilities to exercise control over individuals and communities. In particular, those who are marginalized. Additionally, reproductive oppression is rooted in the historical and ongoing struggle for reproductive rights among marginalized individuals – primarily focusing on how power and control are exercised and enforced over reproduction and reproduction-related choices.
The sexual and reproductive exploitation of enslaved Black women was a direct result of their dehumanization and the denial of their fundamental rights as individuals. Enslavers often encouraged and sometimes forced sexual relations between enslaved individuals, particularly between Black women and men, to increase their holdings and, ultimately, the profitability of enslaved people. The slave breeding system was rooted in the economic benefits derived from the labor of enslaved people. Black women's bodies were seen as a source of profit, and their reproductive capabilities were valued for the production of new enslaved people.
However, reproductive oppression did not stop after the emancipation of enslaved Black Americans and has been the foundation of eugenics legislation that forcibly sterilized marginalized communities. Other examples of reproductive oppression include limiting access to contraception, discriminatory healthcare practices and bias, and mass incarceration -- which can impact reproductive health and rights, with incarcerated women often facing barriers to accessing reproductive healthcare and discrimination. Some argue that a more recent and more nuanced example of reproductive oppression is currently happening in Georgia, where Adriana Smith, a 30-year-old nurse and mother, was declared brain-dead after suffering a medical emergency. At the time, Smith was nine weeks pregnant.
Despite being declared brain dead, Emory University Hospital is keeping Smith's organs functioning on life support until the fetus can be delivered due to Georgia's law banning most abortions after fetal cardiac activity is detected or about six weeks into pregnancy. Smith is currently 22 weeks pregnant and has been on life support for more than 90 days. This has been a heart-wrenching and excruciating experience for Smith's family, who simply wants the choice to act on Smith's behalf in a way that they feel their loved one would have wanted. As the current socio-political climate continues to change in the U.S., some fear the future of reproductive rights and the possibility of reproductive oppression being exercised in more overt and harmful ways, such as how Black women have been treated in the country for centuries.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best hot stocks to buy according to Wall Street analysts. On July 3, Bloomberg News reported that AstraZeneca (NASDAQ:AZN) is in discussions with Summit Therapeutics for a licensing agreement concerning an experimental lung cancer drug, with a potential value of up to $15 billion. The proposed deal for the drug, which is known as ivonescimab, could involve an upfront payment of several billion dollars to Summit, in addition to future milestone payments. However, the talks are ongoing and could still fall apart. Summit might even choose to partner with a different company. Neither Summit nor AstraZeneca has officially commented on the report. A laboratory employee in a sterile environment inspecting a microscope focused on a Clostridioides difficile infection sample. Summit Therapeutics secured the rights to ivonescimab through a separate deal worth up to $5 billion with China-based Akeso in December 2022. Under that agreement, Summit gained exclusive rights to develop and commercialize ivonescimab in the US, Canada, Europe, and Japan, while Akeso (OTC:AKESF) retained rights for other regions, including China. The deal included an upfront payment of $500 million to Akeso and potential regulatory and commercial milestones of up to $4.5 billion. Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company that discovers, develops, and commercializes patient, physician, caregiver, and societal-friendly medicinal therapies. AstraZeneca (NASDAQ:AZN) is a biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines. While we acknowledge the potential of SMMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 minutes ago
- Yahoo
Citizens JMP Reiterates a Buy Rating on Dynavax Technologies (DVAX) With a Price Target of $31
Dynavax Technologies Corporation (NASDAQ:DVAX) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 23, Citizens JMP analyst Roy Buchanan reiterated a Buy rating on Dynavax Technologies Corporation (NASDAQ:DVAX) and set a price target of $31.00. A biopharmaceutical company executive signing a collaboration agreement with a partner. The company reported record net product revenue for HEPLISAV-B in fiscal Q1 2025, reaching $65 million and showing a 36% year-over-year growth. HEPLISAV-B is the first and only adult vaccine for hepatitis B approved in the US, the UK, and the EU. Its total estimated market share in the US rose to around 43%, compared to around 41% in fiscal Q1 2024. Dynavax Technologies Corporation (NASDAQ:DVAX) also announced plans for the new pandemic influenza adjuvant program and Lyme disease vaccine programs to enter clinical development in 2025 and 2027, respectively. In addition, the company expects top-line results in Part 1 of the Phase 1/2 shingles vaccine trial by fiscal Q3 2025. Dynavax Technologies Corporation (NASDAQ:DVAX) is a biopharmaceutical company that discovers, develops, and commercializes novel vaccines and immuno-oncology therapeutics. The company's product pipeline includes HEPLISAV-B, a vaccine for all known subtypes of the hepatitis B virus in adults aged 18 and above. While we acknowledge the potential of DVAX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
19 minutes ago
- Yahoo
Revolution Medicines, Summit Therapeutics Partner on RAS Inhibitor/Ivonescimab Combinations for Solid Tumors
Revolution Medicines Inc. (NASDAQ:RVMD) is one of the best high short interest stocks with huge upside potential. On June 30, Revolution Medicines and Summit Therapeutics Inc. (NASDAQ:SMMT) announced a clinical collaboration to evaluate combinations of Revolution Medicines' investigational RAS(-ON) inhibitors with Summit Therapeutics' ivonescimab in multiple solid tumor settings. The collaboration will assess the safety and efficacy of these combinations in RAS mutant non-small cell lung cancer/NSCLC, pancreatic ductal adenocarcinoma/PDAC, and colorectal cancer/CRC. Under the agreement, Summit Therapeutics will supply ivonescimab for clinical research, while Revolution Medicines will serve as the study sponsor. Both companies will retain commercial rights to their respective compounds. A researcher poring over test results, illustrating the breakthrough potential of biotechnology. The agreement is mutually non-exclusive, allowing each company to pursue additional partnerships. Revolution Medicines will contribute 3 of its clinical-stage RAS(-ON) inhibitors to the collaboration: daraxonrasib (RMC-6236), which is a multi-selective inhibitor; zoldonrasib (RMC-9805), which is a G12D-selective inhibitor; and elironrasib (RMC-6291), which is a G12C-selective inhibitor. Revolution Medicines Inc. (NASDAQ:RVMD) is a clinical-stage precision oncology company that develops novel targeted therapies for RAS-addicted cancers. Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company. While we acknowledge the potential of RVMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio